128 related articles for article (PubMed ID: 35357473)
1. Hitzler J, Alonzo T, Gerbing R, et al. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood. 2021;138(23):2337-2346.
Blood; 2022 Mar; 139(13):2085. PubMed ID: 35357473
[No Abstract] [Full Text] [Related]
2. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
Hitzler J; Alonzo T; Gerbing R; Beckman A; Hirsch B; Raimondi S; Chisholm K; Viola S; Brodersen L; Loken M; Tong S; Druley T; O'Brien M; Hijiya N; Heerema-McKenney A; Wang YC; Schore R; Taub J; Gamis A; Kolb EA; Berman JN
Blood; 2021 Dec; 138(23):2337-2346. PubMed ID: 34320162
[TBL] [Abstract][Full Text] [Related]
3. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Taub JW; Berman JN; Hitzler JK; Sorrell AD; Lacayo NJ; Mast K; Head D; Raimondi S; Hirsch B; Ge Y; Gerbing RB; Wang YC; Alonzo TA; Campana D; Coustan-Smith E; Mathew P; Gamis AS
Blood; 2017 Jun; 129(25):3304-3313. PubMed ID: 28389462
[TBL] [Abstract][Full Text] [Related]
4. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.
Balsat M; Renneville A; Thomas X; de Botton S; Caillot D; Marceau A; Lemasle E; Marolleau JP; Nibourel O; Berthon C; Raffoux E; Pigneux A; Rodriguez C; Vey N; Cayuela JM; Hayette S; Braun T; Coudé MM; Terre C; Celli-Lebras K; Dombret H; Preudhomme C; Boissel N
J Clin Oncol; 2017 Jan; 35(2):185-193. PubMed ID: 28056203
[TBL] [Abstract][Full Text] [Related]
5. Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study.
Flasinski M; Scheibke K; Zimmermann M; Creutzig U; Reinhardt K; Verwer F; de Haas V; van der Velden VHJ; von Neuhoff C; Zwaan CM; Reinhardt D; Klusmann JH
Blood Adv; 2018 Jul; 2(13):1532-1540. PubMed ID: 29959152
[TBL] [Abstract][Full Text] [Related]
6. A mind map for managing minimal residual disease in acute myeloid leukemia.
Benton CB; Ravandi F
Clin Adv Hematol Oncol; 2017 Nov; 15(11):859-867. PubMed ID: 29200419
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Flow Cytometry Identified "Minimal Residual Disease" (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma.
Gu J; Liu J; Chen M; Huang B; Li J
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2568-2574. PubMed ID: 30142420
[TBL] [Abstract][Full Text] [Related]
8. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.
Escherich G; Zur Stadt U; Borkhardt A; Dilloo D; Faber J; Feuchtinger T; Imschweiler T; Jorch N; Pekrun A; Schmid I; Schramm F; Spohn M; Zimmermann M; Horstmann MA
Haematologica; 2022 May; 107(5):1026-1033. PubMed ID: 34348455
[TBL] [Abstract][Full Text] [Related]
10. Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Simoes C; Paiva B; Martínez-Cuadrón D; Bergua JM; Vives S; Algarra L; Tormo M; Martinez P; Serrano J; Herrera P; Ramos F; Salamero O; Lavilla E; Gil C; Lopez JL; Vidriales MB; Labrador J; Falantes JF; Sayas MJ; Ayala R; Martinez-Lopez J; Villar S; Calasanz MJ; Prosper F; San-Miguel JF; Sanz MÁ; Montesinos P
Blood Adv; 2021 Feb; 5(3):760-770. PubMed ID: 33560390
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
[TBL] [Abstract][Full Text] [Related]
12. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
Ravandi F; Jorgensen J; Borthakur G; Jabbour E; Kadia T; Pierce S; Brandt M; Wang S; Konoplev S; Wang X; Huang X; Daver N; DiNardo C; Andreeff M; Konopleva M; Estrov Z; Garcia-Manero G; Cortes J; Kantarjian H
Cancer; 2017 Feb; 123(3):426-435. PubMed ID: 27657543
[TBL] [Abstract][Full Text] [Related]
13. Optimized clinical application of minimal residual disease in acute myeloid leukemia with RUNX1-RUNX1T1.
Wei H; Liu X; Wang Y; Lin D; Zhou C; Liu B; Qiu S; Gu R; Li Y; Wei S; Gong B; Liu K; Gong X; Liu Y; Zhang G; Fang Q; Zhang J; Jin J; Ma Y; Mi Y; Wang J
Exp Hematol; 2021 Apr; 96():63-72.e3. PubMed ID: 33524443
[TBL] [Abstract][Full Text] [Related]
14. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group.
Rau RE; Dai Y; Devidas M; Rabin KR; Zweidler-McKay P; Angiolillo A; Schore RJ; Burke MJ; Salzer WL; Heerema NA; Carroll AJ; Winick NJ; Hunger SP; Raetz EA; Loh ML; Wood BL; Borowitz MJ
Pediatr Blood Cancer; 2021 Apr; 68(4):e28929. PubMed ID: 33559396
[TBL] [Abstract][Full Text] [Related]
17. Impact of pre-transplantation minimal residual disease (MRD) on the outcome of Allogeneic hematopoietic stem cell transplantation for acute leukemia.
Shen X; Pan J; Qi C; Feng Y; Wu H; Qian S; Lu H; Chen L; Li J; Miao K; Qiu H; Zhu H
Hematology; 2021 Dec; 26(1):295-300. PubMed ID: 33648437
[TBL] [Abstract][Full Text] [Related]
18. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
Setiadi A; Owen D; Tsang A; Milner R; Vercauteren S
Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
[TBL] [Abstract][Full Text] [Related]
19. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
Stone RM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):509-14. PubMed ID: 22127313
[TBL] [Abstract][Full Text] [Related]
20. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
